Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02118987 · ClinicalTrials.gov registry record · Phase 1
Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02118987: Completed Phase 1 study, sponsored by Dana-Farber Cancer Institute.
NCT02118987 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02118987, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recurring and allowing the participant to be treated with the chemotherapy the participant's oncologist prefers to give.
Primary Outcome
Measure percentage of patients able to undergo reaction-free desensitizations.
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-07 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
What the finished NCT02118987 record still lists
NCT02118987 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT02118987 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02118987 about?
NCT02118987 is a clinical study titled "Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization". This research study is evaluating a drug called omalizumab (brand name 'Xolair') as a potential treatment to be used in conjunction with drug desensitization to prevent reactions from recurring and allowing the participant to be treated with the chemotherapy the participant's oncologist prefers to g...
What is the current status of trial NCT02118987?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2014-07. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02118987?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT02118987?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02118987's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia